Below is a summary of our recent news. Click any post title or the read more link below any story to see more!
Please join us in Denver, CO on October 20th for a patient education seminar on Graves' disease and thyroid eye disease! The event is free, but advance registration is requested to reserve space.
We'd like to thank our friends at ThyCa: Thyroid Cancer Survivors', Inc. for the opportunity to host this meeting during their annual conference. If you or a loved one has been impacted by thyroid cancer, please consider attending the full ThyCa conference from Oct. 18-20!
The GDATF is excited to announce three upcoming events for patients and family members! On Saturday, October 5th, we're headed to Tempe, AZ (just outside Phoenix) for a full-day event. Please click here for details and registration!
On Sunday, October 20th, we'll be in Denver, CO to host a half-day seminar in conjunction with the ThyCa: Thyroid Cancer Survivors', Inc. annual patient conference. Please click here for speakers and registration! We are grateful to our friends at ThyCa for this opportunity! If you or a loved one has been impacted by thyroid cancer, please consider attending their full conference, which runs from Friday, October 18th - Sunday, October 20th. For details and registration for the full conference, please visit http://thyca.org/support/conferences/.
Finally, we are excited to be attending the American Thyroid Association's 89th Annual Meeting in Chicago, IL, which will include a public patient forum on Saturday, November 2nd. This event is hosted by the American Thyroid Association (ATA) Alliance for Patient Education, and will be a great opportunity for patients to interact with advocates and physicians in an informal setting. Details and registration coming soon!
If you enjoyed the GDATF's patient bulletin "What's Wrong With Me? I'm Not Myself Anymore", then you won't want to miss the sequel! "A survey study of neuropsychiatric complaints in patients with Graves’ disease: A reassessment of self-reported symptoms and current practice 20 years later" is now available as an e-manuscript that is free with Kindle Unlimited or $2.99 with Amazon. Many thanks to Dr. James Arruda for conducting this important research - and for donating 70% of the proceeds to the GDATF! Click here for more info!
We're headed to Seattle! Please join us for a special patient education event on Sunday, June 30th from 8:30 a.m. until 4:30 p.m.! This event is FREE, but advance registration is reqired to reserve space. Please click here to view the agenda or click here for location and registration!
Horizon Pharma has just released top line results for the Phase III trial of Teprotumumab, a potential new treatment for thyroid eye disease. Detailed Phase III data will be submitted for publication in a peer-reviewed journal and presented at a medical congress later this year. Click this link to learn more: http://bit.ly/2ECfINj
Raymond Douglas, M.D., Ph.D., the study’s co-principal investigator, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, and a member of the GDATF's Physician Advisory Board stated: “In the study, patients treated with teprotumumab had an unprecedented reduction in proptosis [eye bulging], which is currently only treatable via surgery after the active disease has ended. If approved, teprotumumab would give physicians the first medicine shown to reduce proptosis during active thyroid eye disease, in addition to treating other painful symptoms.”